Rosiglitazone, a peroxisome proliferator-activated receptor-γ agonist, attenuates airway inflammation by inhibiting the proliferation of effector T cells in a murine model of neutrophilic asthma

Immunology Letters

Volumn 157, Issue 1-2, 2014, Pages 9-15

  Zhao, Yan ^a   Huang, Yi ^b   He, Jing ^a   Li, Changyi ^a   Deng, Wang ^a   Ran, Xuemei ^a   Wang, Daoxin ^a  

^a THE SECOND AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Asthma; Neutrophils; Peroxisome proliferator activated receptor (PPAR ); Rosiglitazone; T helper 17 (Th17)

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; BIOTINYLATION; CD4+ T LYMPHOCYTE; CELL VIABILITY; COCULTURE; CONTROLLED STUDY; EFFECTOR CELL; FEMALE; IMMUNE RESPONSE; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; MOUSE; NEUTROPHIL; NEUTROPHIL COUNT; NEUTROPHILIC ASTHMA; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION;

ASTHMA; NEUTROPHILS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-Γ (PPARΓ); ROSIGLITAZONE; T HELPER 17 (TH17);

ANILIDES; ANIMALS; ANTIBODY SPECIFICITY; ASTHMA; BRONCHOALVEOLAR LAVAGE FLUID; CELL DIFFERENTIATION; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION; IMMUNOGLOBULIN E; INFLAMMATION MEDIATORS; INTERLEUKIN-17; LUNG; LYMPHOCYTE ACTIVATION; MICE; NEUTROPHILS; OVALBUMIN; PPAR GAMMA; T-LYMPHOCYTE SUBSETS; THIAZOLIDINEDIONES;

EID: 84888780014     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2013.11.004     Document Type: Article

References (35)

1. Gavett S.H., Chen X., Finkelman F., Wills-Karp M. Depletion of murine CD4+ T lymphocytes prevents antigen-induced airway hyperreactivity and pulmonary eosinophilia. American Journal of Respiratory Cell and Molecular Biology 1994, 10:587.
2. Lambrecht B.N., Veerman M.D., Coyle A.J., Gutierrez-Ramos J.-C., Thielemans K., Pauwels R.A. Myeloid dendritic cells induce Th2 responses to inhaled antigen, leading to eosinophilic airway inflammation. Journal of Clinical Investigation 2000, 106:551-559.
3. Larché M., Robinson D.S., Kay A.B. The role of T lymphocytes in the pathogenesis of asthma. Journal of Allergy and Clinical Immunology 2003, 111:450-463.
4. Bateman E.D., Hurd S.S., Barnes P.J., Bousquet J., Drazen J.M., FitzGerald M., et al. Global strategy for asthma management and prevention: GINA executive summary. European Respiratory Journal: Official Journal of the European Society for Clinical Respiratory Physiology 2008, 31:143-178.
5. Green CEB R.H., Woltmann G., Parker D., Wardlaw A.J., Pavord I.D. Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax 2002, 57:875-879.
6. Fossiez F., Djossou O., Chomarat P., Flores-Romo L., Ait-Yahia S., Maat C., et al. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. Journal of Experimental Medicine 1996, 183:2593-2603.
7. Martti Laan Cui Z.-H., Hoshino H., Lötvall J., Sjöstrand M., Gruenert D.C., et al. Neutrophil recruitment by human IL-17 via CXC chemokine release in the airways. Journal of Immunology 1999, 162:2347-2352.
8. Cosmi L., Liotta F., Maggi E., Romagnani S., Annunziato F. Th17 cells: new players in asthma pathogenesis. Allergy 2011, 66:989-998.
9. Issemann I., Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990, 347:645.
10. Berger J., Moller D.E. The mechanisms of action of PPARs. Annual Review of Medicine 2002, 53:409-435.
11. Park S.J., Lee Y.C. Peroxisome proliferator-activated receptor gamma as a novel therapeutic target in asthma. Journal of Asthma: Official Journal of the Association for the Care of Asthma 2008, 45:1-8.
12. Knouff C., Auwerx J. Peroxisome proliferator-activated receptor-γ calls for activation in moderation: lessons from genetics and pharmacology. Endocrine Reviews 2004, 25:899-918.
13. Pershadsingh H.A. Peroxisome proliferator-activated receptor-γ: therapeutic target for diseases beyond diabetes: quo vadis. Expert Opinion on Investigational Drugs 2004, 13:215-228.
14. Glass C.K., Saijo K. Nuclear receptor transrepression pathways that regulate inflammation in macrophages and T cells. Nature Reviews Immunology 2010, 10:365-376.
15. Kim S.H., Hong J.H., Lee Y.C. Ursolic acid, a potential PPARgama agonist, suppresses ovalbumin-induced airway inflammation and Penh by down-regulating IL-5, IL-13, and IL-17 in a mouse model of allergic asthma. European Journal of Pharmacology 2013, 701:131-143.
16. Moseman E.A., Liang X., Dawson A.J., Panoskaltsis-Mortari A., Krieg A.M., Liu Y-J., et al. Human plasmacytoid dendritic cells activated by CpG oligodeoxynucleotides induce the generation of CD4+ CD25+ regulatory T cells. Journal of Immunology 2004, 173:4433-4442.
17. Hamida Hammad H.J.D.H., Soullie T., Lambrecht B.N. Activation of peroxisome proliferator-activated receptor-γ in dendritic cells inhibits the development of eosinophilic airway inflammation in a mouse model of asthma. American Journal of Pathology 2004, 164:263-271.
18. Wilson R.H., Whitehead G.S., Nakano H., Free M.E., Kolls J.K., Cook D.N. Allergic sensitization through the airway primes Th17-dependent neutrophilia and airway hyperresponsiveness. American Journal of Respiratory and Critical Care Medicine 2009, 180:720-730.
19. Woerly G., Honda K., Loyens M., Papin J-P., Auwerx J., Staels B., et al. Peroxisome proliferator activated receptors α and γ down-regulate allergic inflammation and eosinophil activation. Journal of Experimental Medicine 2003, 198:411-421.
20. Zhu T., Zhang W., Wang D.-X., Huang N.-W., Bo H., Deng W., et al. Rosuvastatin attenuates mucus secretion in a murine model of chronic asthma by inhibiting the gamma-aminobutyric acid type A receptor. Chinese Medical Journal 2012, 125:1457-1464.
21. Koya T., Matsuda H., Matsubara S., Miyahara N., Dakhama A., Takeda K., et al. Differential effects of dendritic cell transfer on airway hyperresponsiveness and inflammation. American Journal of Respiratory Cell and Molecular Biology 2009, 41:271-280.
22. Daan de Boer J., Roelofs J.J., de Vos A.F., de Beer R., Schouten M., Hommes T.J., et al. Lipopolysaccharide inhibits Th2 lung inflammation induced by house dust mite allergens in mice. American Journal of Respiratory Cell and Molecular Biology 2013, 48:382-389.
23. Seys S., Grabowski M., Adriaensen W., Decraene A., Dilissen E., Vanoirbeek J., et al. Sputum cytokine mapping reveals an 'IL-5, IL-17A, IL-25-high' pattern associated with poorly controlled asthma. Clinical and Experimental Allergy 2013, 43:1009-1017.
24. Zou Y., Sonderegger I., Lipowsky G., Jennings G.T., Schmitz N., Landi M., et al. Combined vaccination against IL-5 and eotaxin blocks eosinophilia in mice. Vaccine 2010, 28:3192-3200.
25. Foster P.S., Hogan S.P., Ramsay A.J., Matthaei K.I., Young I.G. Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model. Journal of Experimental Medicine 1996, 183:195-201.
26. Eagan R.W., Athwahl D., Chou C.-C, Emtage S., Hehn C.-H., Kung T.T., et al. Inhibition of pulmonary eosinophilia and hyperreactivity by antibodies to lnterleukin-5. International Archives of Allergy and Immunology 1995, 107:321-322.
27. Pavord I.D., Korn S., Howarth P., Bleecker E.R., Buhl R., Keene O.N., et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012, 380:651-659.
28. Zhao Y., Yang J., Gao Y.-D., Guo W. Th17 immunity in patients with allergic asthma. International Archives of Allergy and Immunology 2009, 151:297-307.
29. Alcorn J.F., Crowe C.R., Kolls J.K. TH17 cells in asthma and COPD. Annual Review of Physiology 2010, 72:495-516.
30. Kudo M., Melton A.C., Chen C., Engler M.B., Huang K.E., Ren X., et al. IL-17A produced by [alpha][beta] T cells drives airway hyper-responsiveness in mice and enhances mouse and human airway smooth muscle contraction. Nature Medicine 2012, 18:547-554.
31. Bullens D.M., Truyen E., Coteur L., Dilissen E., Hellings P.W., Dupont L.J., et al. IL-17 mRNA in sputum of asthmatic patients: linking T cell driven inflammation and granulocytic influx?. Respiratory Research 2006, 7:135.
32. Agache I., Ciobanu C., Agache C., Anghel M. Increased serum IL-17 is an independent risk factor for severe asthma. Respiratory Medicine 2010, 104:1131-1137.
33. Wang Y.H., Voo K.S., Liu B., Chen C.Y., Uygungil B., Spoede W., et al. A novel subset of CD4(+) T(H)2 memory/effector cells that produce inflammatory IL-17 cytokine and promote the exacerbation of chronic allergic asthma. Journal of Experimental Medicine 2010, 207:2479-2491.
34. van Rijt L.S., Lambrecht B.N. Dendritic cells in asthma: a target for novel therapeutics?. Drug Discovery Today: Therapeutic Strategies 2006, 3:299-307.
35. Kool M., Lambrecht B.N. Dendritic cells in asthma and COPD: opportunities for drug development. Current Opinion in Immunology 2007, 19:701-710.